Bob Lanier
Dr.
Bobby Lanier was the 98th president to the Tarrant County Medical Society.
He is also Past President of the
Dr. Lanier and his wife Sandy and their two children arrived
in
After a pediatric internship at UTMB, Dr. Lanier served in the Air Force and
completed a Pediatric Residency at
Dr. Lanier founded Fort Worth Allergy and Asthma Associates in 1977 and
continues in active practice at North Texas Institute for Clinical
trials. He sustains a practice for the indigent and non-insured
community and as medical director of Lanier Education and Research Network, a
corporation devoted to educational technology and pharmaceutical research.
Dr. Lanier founded the Society of Principal Investors, a professional society
of physicians conducting FDA pharmaceutical trials. Since joining the medical
society in 1977, Dr. Lanier has been involved intensely in communication
efforts. A medical society committee assignment in 1980 led to his
involvement locally with the NBC television affiliate where he served in a
public service capacity from 1981-2001. He has appeared on
“Ophra”, several times on “Nightline with Ted Koppell”,
the “Today Show ”,”Nightly News with Tom Brohaw”, “Good Morning America”,
“Good Morning South Africa” and “Radio Zulu”. Dr. Lanier founded the National Association
of Physician Broadcasters. Dr. Lanier also served as an NBC television
network correspondent from 1982-1985 after which time his television segments
were internationally syndicated daily to over 100 television markets and heard
in over 250 radio stations in this country and worldwide through the Armed
Forces Radio and Television Network. Dr. Lanier founded the National
Association of Physician Broadcasters. He was honored in 1995 by the
American 
Medical
Association with the Education and Research Foundations award for public
communications.
Dr. Lanier stood for public office ( Congressional District 12) in 1989 and was defeated by Rep. Pete Geren . Dr. Lanier co-chaired the successful Congressional campaign of Representative Kay Granger.
Dr. Lanier is a passionate fisherman, photographer, and sports writer .His
articles and photographs have appeared in in-flight and sports
magazines. He has written over 400 articles on sports fishing for
magazines such as Saltwater Sportsman,
BOBBY
QUENTIN LANIER, M.D.
CURRICULUM VITAE
EDUCATION
·
Undergraduate education:
·
Professional education:
·
Post-graduate professional education:
Internship -
(Pediatrics, 1970-1971)
Residency -
(Pediatrics, 1971-1973) Certification, 1975
Fellowship:
(Immunology 1973-1975) Certification,
(1977)
·
Certified Clinical Research Investigator: Association of Clinical
Research Professionals (2002)
·
Certified Clinical Research Investigator:
AWARDS
·
Achievement
Award, American Lung Association of
·
Bela Schick Lecture, American
·
Distinguished Fellow,
·
American Medical Association, Education and Research Foundation Award
For Health Education (1994)
·
Distinguished
·
Heart Association Paul R. Ellis Media Award (1990, 1994, 1998)
·
·
Best Documentary “Cancer:
·
Achievement of Excellence, documentary “Cancer: Texas Strikes Back”
·
(1980, 1981, 1982, 1983, 1984,
1985, 1986)
PROFESSIONAL EXPERIENCE
·
Clinical Professor of Pediatrics: University of
·
Editorial Board Proceedings of Allergy Asthma and Immunology (2004
– present)
·
Editor -
·
Editor – John Hopkins, Asthma Monitor (2001-2002)
·
Medical Director- North Texas Institute for Clinical Trials:
(1982-present)
·
Founder and Executive Director- Medical Media Network: (1982-present)
·
Private Practice- (1977- 1999)
·
Founder:
·
Chief / training director - Ped Allergy/Immunology, Wilford Hall USAF
EXECUTIVE POSITIONS HELD
·
Board of Directors, World Allergy Organization (2005- present)
·
President – Association of Certified Allergists (2002-2003)
·
President -
·
President:
·
President:
·
Founder/EVP: Society of Principal Investigators (2000 – present)
·
Board of Directors; Texas Medical Association Foundation (1998-present)
·
Chairman: AllerDays Research Council for HMR (1997-1999)
·
Chairman: Managed Care Council:
and Immunology (1995-1996)
·
President:
·
Treasurer:
·
Founder and Executive Director:
Communicators (1990- present)
·
Delegate (alt) American Medical Association American College of Allergy
Asthma
and Immunology (1990-present)
·
Board of Directors: Joint Council of Allergy and Immunology (1990-1995)
·
Senior Vice President Harris Methodist Health System, Communications
Research (1989- 1998)
·
Anchor / Editor: Medical Economics
Video Magazine (1989 - 1995)
·
Board of Regents, Executive Committee,
Immunology (1989- 1995)
·
Chairman: International Allergy Group for Scherring Corporation
(1989-1993)
·
President, National Association of Physician Broadcasters (1989-1991)
·
Nominee for Congress, District 12
(1989)
·
Chairman, Joint Marketing Task Force,
Immunology (1987-1990)
·
Chairman, Public Education Task Force on Cancer (1987)
·
Founder, National Association of Physician Broadcasters (1986-1991)
·
Medical Consultant, NBC News (1984-1986)
·
Co-Chairman,
·
Chairman, Council on Communications,
Association (1984-1985)
·
Medical Director, North Texas Institute for Clinical Trials,
(1982-Present)
·
Founder/CEO - Bob Lanier, MultiMedia - (1982 - present) A medical
communications and video corporation
·
Medical Consultant, KXAS TV, (NBC) (1981 - 1998)
PROFESSIONAL ORGANIZATIONS
·
World Allergy Organization (2001 – present)
·
American
·
Alternate Delegate (
American Medical
Assoc., (1991- present)
·
Society of Professional Journalists (1988-present)
·
Radio & Television News Directors Association (1987-present)
·
Board of Directors, American Lung Association (1984-1985)
·
·
American Medical Association (1979-present)
·
Texas Medical Association (1979-present)
·
Tarrant County Pediatric Society (1979-present)
·
Fellow,
·
Board of Directors,
·
Board of Directors,
·
American Association of Certified Allergists (1977-present)
·
Fellow,
·
Diplomat, American Board of Pediatrics (1975-present)
·
Phi Beta Phi Medical Fraternity (1966-present)
TEACHING POSITIONS
·
Clinical Professor of Pediatrics: University of
·
Faculty: Pilot program Scientific Communications fellowship World Allergy
Organization (2006)
·
Assistant Clinical Professor, Department of Medicine
·
Faculty, American Medical Association - Annual Health Reporting
Conference (1982-1990)
·
Supervisor: Clerkships for Family Practice Residents,
·
Director Allergy division:
Department of Family Practice,
·
Attending physician: Division of
Internal Medicine and Family Practice,
COMMUNITY ORGANIZATIONS
·
Advisory Board of Directors, Samaritan Housing for AIDS (1997-present)
·
Advisory Board, Tarrant
·
Advisory Board of Directors,
·
Advisory Board Member, American Institute for Teen AIDS Prevention
(1990-present)
·
Spokesperson, Kid Care - Volunteer Connection, KXAS-TV (1990-1998)
·
Finance and Executive Board, First United
·
Board of Directors: Women with Aids (a childcare facility for the
children of
families with AIDS) (1988)
·
Board of Directors:
Medical Facility) (1984-1998)
·
Board of Directors, Salvation Army (1983-1987)
·
Founder, Asthma Camp for Children, "
·
Board of Directors, Citizens Advisory Council for Cable Television
(1981-1983)
·
Board of Directors, Camp Carter-YMCA (1981-1983)
MEDIA EXPERIENCE
·
Oprah, 1999, “Surviving a Hospital Stay”
·
Talent: Schering Cable television half hour : Allergies - fact and myth (
1995)
·
Talent: Schering Cable television half hour: Allergies- how to survive (1995)
·
Talent: "Medical Talk Etc..."
KCBI Radio - weekly medical talk show (1991- 1993)
·
Medical reporter - KCBI Radio (1990-present)
·
Anchor: Medical Economics Video
Magazine, a quarterly broadcast
and tape (1989-1995)
·
Medical commentator - WBAP Radio (1985-2001)
·
Talent, Writer, Producer: Sixty Second Housecall, daily national
radio/television commentary in syndication
(1985- 2001)
·
Nightline Guest (ABC), Jan. 1985, "The Fate of Private
Practice".
·
Medical Reporter, KXAS TV, (NBC) (1981 - Present)
·
NBC "A" News correspondent (1984-1986)
·
Medical commentator - "Master Control", Southern Baptist
Radio/TV
Commission (1984-1986)
·
Nightline Guest (ABC), July 1984, "Controversies in Allergy".
·
Medical commentator: Medical Portfolio - an audio cassette journal
(1983-present)
·
Talent, producer, writer: Glaxo- “Overview of Allergy (Introductory videotape)
·
Talent, writer, producer: Glaxo- “Overview of Asthma (Introductory videotape)
·
Talent, writer, producer: “Good news about heart attack
treatment” 30 minute
broadcast documentary (1990)
BOOKS
·
Textbook Chapter, Anti-IgE “Atlas of Allergy” Blaiss,
Liberman 2005
·
The Physician as Communicator - a text of communication skills for
physicians.
·
The New Epidemic: A Patient
Survival Guide to Asthma (in progress)
·
CD-ROM: Interactive Cases in Asthma (1995)
·
CD-i Interactive Asthma Education
Series
PUBLICATIONS
- Marple BF, Fornadley JA, Patel AA, Fineman SM, Fromer L, Krouse JH, Lanier BQ, Penna P; Keys to successful management of patients with allergic rhinitis: focus on patient confidence, compliance, and satisfaction. Otolaryngol Head Neck Surg. 2007 Jun;136(6 Suppl):S107-24.
- Lanier B; Allergic rhinitis: selective comparisons of the pharmaceutical options for management. Allergy Asthma Proc. 2007 Jan-Feb;28(1):16-9. Review.
- Lanier BQ: Epinastine 0.05% for the Treatment of Allergic Conjunctivitis, Expert Review of Opthamology, in press
- Liping, W, Yin,j Lanier,B Baboon Syndrome Contact Dermatitis 56:356-357, 2007
- Lanier, Bob Q. Unanswered questions and speculations about the role of anti-immunologlobulin E in atopic and nonatopic disease , Allergy Asthma Proceedings Vol. 27, No. 2 March-April 2006, Supplement No.1
- Lanier, Bob Q. Unanswered Questions and Warnings Involving Anti–Immunoglobulin E Therapy Based on 2-Year Observation of Clinical Experience Proceedings of Allergy Asthma and ImmunologyVolume 26, Number 6, November-December 2005 pp. 435-439(5)
- Lanier
BQ, Abstract: Anaphylaxis
with SIT while being treated with Xolair European
- Lanier BQ, Abstract: " IgE does not
consistently rise with anti-IgE therapy" presented at ACAAI annual
meeting 2005 Nov 2005,
- Lanier BQ, Abstract: " IgE does not
protect against anaphylaxis with SIT" presented at ACAAI annual
meeting 2005 Nov.2005,
- Lanier BQ, Abstract: " Safety and
Efficacy of Olepatidine .6% Nasal spral in Perienial allergic
rhinitis" presented at AAAAI annual meeting 2006, March 2006
- Lanier BQ,
Allergy- On The Rise and in the News, Refractive Eyecare Feb 2006 V10 Number 2
- Lanier BQ, Hampel F, Kittner B, Varghese ST, Safety Of Fexofenadine In Pre-School
Children With Allergic Rhinitis, Abstract, American Academy of
Pediatics, 2005 National Confernece and Exhibition October 2005,
Washington, D.C.
- BQ Lanier, Editorial Board: Allergy and Asthma Proceedings, (under academic appointments)
- G.Shapiro, G. Bensch R. Lanier, L. Sher M. Lloyd, S.
Kundu, J. Williams, D. Banerji, Once-daily treatment with ciclesonide is
effective and well tolerated in children with persistent asthma, Abstract,
annual meeting AAAAI, 2005 San Antonio, Texas
- Lanier BQ, Miller
D, Omalizumab is well tolerated in adolescent/adult patients(>=12
years) with moderate-to-severe persistent asthma, Abstract presented at
ATS Meeting, May 2005
- Lanier BQ, Casale
TB, Omalizumab is well tolerated in adolescent/adult patients(>=12
years) with moderate-to-severe persistent asthma, Abstract presented at
AAAI Annual Meeting, March 2005
- Lanier BQ,
textbook chapter, Blaiss Atlas of Allergy and Immunology – in press
- Lanier BQ,
textbook chapter, Leiberman and Anderson, Allergy and Immunology –
in press
- Lanier BQ, Chang
TW, Will Anti-IgE therapt Comprimise Normal Immune Functions?, Allergy
& Clinical Immunology International, Nov/Dec 2004
- Lanier BQ, Carr
W, Omalizumab in the Treatment of Allergy and Asthma, Drug profile, Therapy
2004 1(1)25-30
- Lanier BQ,
Finegold I, D’Arienzo PA, Clinical Effecacy of Olopatadine vs
epinsatine ophthalmic solution in the conjunctival allergen challenge
Model, Current Medical Research, Aug 2004
- Johansson SG,
Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, Motala C, Ortega
Martell JA, Platts-Mills TA, Ring J, Thien F, Van Cauwenberge P, Williams
HC. Revised nomenclature for allergy for global use: Report of the
Nomenclature Review Committee of the World Allergy Organization, October
2003.J Allergy Clin Immunol. 2004 May;113(5):832-6.
- Lanier, BQ,
Marshall GD Jr, Unanswered questions on Omalzumab (Xolair) patient
Selection and Follow-up, Ann Allergy Asthma Immunol, Feb 2004
- Lanier, BQ,
Analysis of the Efficacy of Technical Presentations As a Means of Sharing
Data and Modifying Behavior of Professionals, Xolair Source, Jan 2004
- Roland PS, Kreisler LS, Reese B, Anon JB, Lanier BQ,
et al, Topical ciprofloxacin/dexamethasone otic suspension is superior to
ofloxacin otic solution in the treatment of children with acute otitis
media with otorrhea through tympanostomy tubes.Pediatrics. 2004 Jan;113(1
Pt 1)
- Lanier BQ,
Patient education doesn’t work-“edu-tainment” does,
Annals of Allergy
Aug 2003
- Lanier BQ, Corren
J, Lumry W, Liu J, Fowler-Taylor AR, Gupta N, Omalizumab is Effective in
the Long-Term Control of Severe Allergic Asthma, Annals of Allergy
Aug 2003
- Lanier, BQ, Newer aspects in the treatment of
pediatric and adult asthma: monoclonal anti-IgE, Ann Allergy Asthma
Immunol. 2003 Jun;90(6 Suppl 3):13-5. Review.
- Lanier BQ,
Ableson MB, Berger WE, Granet DB, D’Arienzo PA, Spanlger DL, Kagi
MK, Comparison of the efficacy of combined fluticasone propionate and
olopatadine versus combined fluticasone propionate and fexofenadine for the treatment of allergic
rhinoconjunctivitis induced by conjunctival allergen challenge, Clinical
Therapeutics, Jul 2002
- Finegold I,
Lanier BQ, Berger W, Blaiss M, Immunotherapy for asthma, Am J Respir Crit
Care Med, May 2002,
15;165(10):1453-4.
- Lanier BQ,
Anti-IgE in the real world, Editorial, Annals of Allergy, May 2002
- Lanier BQ, Busse
W, Corren J, Liu J, Fowler-Taylor AR, Gupta N, Omalizumab is Effective in
the Long-Term Control of Severe Allergic Asthma, Submitted JAMA, 2002
- Weinstein SF(a),
Welch MJ, Lanier BQ, Nayak A, Stampone P, New Beclomethasone Diporionate
Extrafine Aerosol is Effective Pediatric Asthma Therapy, Abstract, 58th
Annual Meeting of the American Academy of Allergy Asthma and Immunology,
New York, USA, March 01-06, 2002
- Lanier BQ, When
the whole is more than the sum of it’s parts, Annals of Allergy,
Asthma, and Immunology, Dec 2001; 87(6): 445-6.
- Busse W, Coren J,
Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, Van As A, Gupta N,
Omalizumab, Anti-IgE Recombinant Humanized Monoclonal Antibody, for the
Treatment of Severe Allergic Asthma, J Allergy Clin Immunol, Aug 2001
108(2):184-90
- Lanier BQ, No
Prescription Needed –No Doctor Either, Annals of Allergy, Asthma
& Immunology, Jul 2001, 87 (1) p1-2, editorial
- Lanier BQ, New
Treatments and the Future Role of Immunotherapy: Anti-IgE, Annals of
Allergy, Asthma & Immunology: Official Publication of the
- Lanier BQ, Gross
R D, Marks B, Cockrum PC, Juniper EF, Olopatadine Ophthalmic Solution
Adjunctive to Loratadine Compared to Loratadine Alone in Patients With
Active Seasonal Allergic Conjunctivitis Symptoms, Annals of Allergy,
Asthma, and Immunology, 2001 Jun; 86(6):641-8.
- Lanier BQ, Berger
WE, D’Arienzo P, Granet
D, Comparison of the Safety and
Efficacy of the Concomitant Use of Flonase® (Fluticasone propionate 5
mcg/aqueous nasal spray) and Patanol® (olopatadine HCl 0.1% ophthalmic
solution) versus Allegra® (Fexofenadine HCl 60 mg capsule and Flonase®
(Fluticasone propionate 50 mcg/aqueous nasal spray) versus placebo in
subjects with allergic rhinoconjunctivitis in the conjunctival allergen
challenge (CAC) model In press, Clinical theraputics
- Tillinghast J(a),
Lanier BQ, Busse W, Chervinsky P,
Ashby M, Fowler-Taylor A, Fick R, Gupta N, Omalizumab Significantly
Increases Time to First Asthma Exacerbation Compared with Placebo, XXth
Congress of the European Academy of Allenology and Clinical Immunology
Berlin, Germany May 09-13 2001
- Lumry W(a),
Berger W, Corren J, Lanier BQ, Busse W, Chervinsky P, Nayak A ,
Fowler-Taylor A, Fick R, Gupta N, Evidence of the Long-term Safety and
Tollerability of Omalizmab from a Large Phase III Study, , XXth Congress
of the European Academy of Allenology and Clinical Immunology Berlin,
Germany May 09-13 2001
- Nelson H, Fick R,
Fowler-Taylor A, Ashby M, Busse W, Chervinsky P, Lanier BQ, Gupta N,
Corren J, Rohane P, Increased Time to First Asthma Exacerbation Seen in
Xolair Treated Patients Compared with Placebo, Ann. Allergy Asthma
Immunol. 86, No.1 98, 2001
- Berger W, Nayak
A, Fowler-Taylor A, Chervinsky P, Busse W, Lanier BQ, Corren J, Gupta N,
Rohane P, Fick R, Long-term Safety and Tolerability of Xolair–A
Double Blind, Placebo–Controlled Study, Ann. Allergy Asthma Immunol.
886, NO.1 , 97, 2001
- Lanier BQ, Fowler-Taylor
A, gupta W, McAlary M, Corren J, Matz J, Townley R, Fick R, Rohane P,
Effect of Severity of Disease on the Efficacy of Xolair – Results
from Two Double-Blind, Placebo-Controlled Studies, Ann. Allergy Asthma
Immunol. 86 No. 1, 82, 2001
- Busse W, Corren
J, Lanier BQ, Everhard F, Surrey K, Kirchdorfer L, Omalizumab Improves
Asthma-specific Quality Of Life (QoL): An Analysis Of Data From 1071
Patients (abstract AAAAI February 2001)
- Busse W, Corren
J, Lanier BQ, Lee T, Nayak A, Chervinsky P, Gibson E, Fick R,
Fowler-Taylor A, Gupta N, RhuMab-E25 (E25), a Novel Therapy for the
Treatment of Allergic Asthma (AA) , Allergy Clin. Immunol. 105, No. 6, Pt.
1, 1246, 2000
- Nayak A, Lanier
BQ, Weinstein S, Welch M, Stampone
Beclomethasone dipropionate extrafine aerosol is safe and effective in
childhood asthma: a 12-week, randomized, double-blind, placebo-controlled
study - Submitted for publication
- Ableson MB,
Lanier BQ, Evaluation of Patenol and Claritin for Allergic Conjunctivitis
using the Conjuctival Antigen Challenge, Ann. Allergy Asthma Immunol. 82,
No. 1, 90, 1999
- Kelsen SG, Lanier
BQ, et al; Salmeterol added to inhaled corticosteroid therapy is superior
to doubling the dose of inhaled corticosteroids: a randomized clinical
trial.
(J Asthma, 1999 Dec)
- Raphael GD,
Lanier BQ, et al; A comparison of multiple doses of fluticasone propionate
and beclomethasone dipropionate in subjects with persistent asthma. (J
Allergy Clin Immunol, 1999 May,
- Nayak AS, Lanier
BQ et al; The effects of triamcinolone acetonide aqueous nasal spray on
adrenocortical function in children with allergic rhinitis. (J Allergy
Clin Immunol, 1998 Feb,)
- Rickard KA,
Kelsen SG, Lanier BQ, Murray JJ, Emmett AH, Anderson WH, Church NL, A Six Month Comparison of Adding
Salmeterol to Doubling the Dose of Beclomethasone (BDP) in Asthma Patients
with Symptoms on Inhaled Corticosteriods, Allergy Clin. Immunol. 101, No
1, Pt. 2, S232, 1998
- Lanier,BQ Multi-media intervention in numerous
emergency room admissions Abstract presented to the
- A. Nayak, M.D.,
G. Feiss, M.S., J.A. Furst, B.S., B. Simpson, B.S., J.A. Smith, M.D.,
- Lanier, BQ,
Sanders, N, The Effect of Asthma Support Groups on Patient Behavior,
Abstract presented to the American College of Allergy, Asthma, and Clinical
Immunology, November 1995
- Szefler, SJ, Lanier BQ, et al Evolving Role of
Theophylline for Treatment of Chronic Childhood Asthma, Journal of
Pediatrics, Vol 127, number 2, pgs
176-185, August 1995
- Lanier BQ;
Confessions of an AMA rookie. (W V Med J, 1993 May)
- Schuller D,
Bellanti JA, Lanier BQ, Oconnell EJ, Scanlon R, Selner JC, Sparks DB,
Storms W, One Organization or 2 0 The Cases For 2 Cooperative, Independent
Societies Versus Reorganization Into One Society, Annals of Allergy, 1993,
v70, n5 (May) p369-381
- Zeitz HJ,
Jamoszuk I, Lanier BQ, Storms WW, Greenstein S, Loratadine-Pseudoephedrine
Combination vs. Clemastine Furnerate-Phenyl Propranolamine Combination in
the Treatment of Seasonal Allergic Rhinitis, Eur. J. Allergy Clin.
Immunol. 47, Suppl. 12, 103, 1992
- Lanier,
B.Q.: Symposium on Pediatric
Asthma, Who's Dying of Asthma and Why., Pediatrics, pgs.838-840, November 1989.
- Grossman J,
Lanier BQ et al; Loratadine-pseudoephedrine combination versus placebo in
patients with seasonal allergic rhinitis. (Ann Allergy, 1989 Oct)
- Grossman J,
Schenkel EC, Bronsky E, Linzmayer J, Selner C, Lanier BQ, Moss BA, Double
Blind Control Study of Loratadine L 5 Mg Plus Pseudoephedrine P 120 Mg
Sch434 In Seasonal Allergic Rhinitis, Sar Ann. Allergy 58 (4), 1987, 280
- Rohr AS, Siegel
SC, Katz RM, Rachelefsky GS, Spector SL, Lanier BQ, A Comparison of
Inhaled Albuterol and Cromolyn in the Prophylaxis of Exercise-Induced
Bronchospasm, Annals of Allergy,
Volume 59, August, 1987.
- Lanier BQ,
Tremblay N, Smith JP, DeFaller JM, A double-masked comparison of ocular
decongestants as therapy for allergic conjunctivitis. (Ann Allergy, 1983
Mar)
- Adinoff A, Tellez
P, Lanier BQ, Fluorocarbon Propellants and Central Nervous System
Stimulation in Asthma, Pediatrics, Sept. 1983, 82 (3) p438-9
- Busy WW, Felman
R., Lanier B., Malbeaux F.J., Munzenberger P., Papaianou H., Rowe M.S.,
Selner J.C., Seltzer J.M., Taylor W.H., White W.T., Terzian E., Mendols
J., Ban AS A., "A two week multi-center double blind dose ranging
study of the comparative efficacy and safety of low-dose sustained
released Benedryl, standard released Benedryl and placebo in out patients
with seasonal allergic rhinitis."
(Protocol 184-56-12-11)
- Smith JP, Lanier
BQ et al; Treatment of allergic conjunctivitis with ocular decongestants.
(Curr Eye Res, 1982)
- Jacobs RL, Lanier
BQ, et al; Adverse reactions to tetanus toxoid, JAMA (The Journal of the
American Medical Association), 1982 Jan, 247 (1) p40-2
- Lanier BQ,
- Lanier, B.: Meat Tenderizer and Stings. Pediatrics,
Vol. 69: 505-6, 1982.
- Rossof, A.H.,
Lanier, B.: Lithium Carbonate
Therapy of the Shwachman Syndrome.
The Pediatric Bulletin,
- Lanier,
Bobby: An Approach to the Medical
Management of Chronic Mouthbreathing (chapter). Moyer's Symposium, Monograph No. 8,
Craniofacial Growth Series, Center for Human Growth and Development,
University of Michigan, Ann Arbor, Michigan, February, 1979.
- Nichols, M.D.,
Lanier, B.Q., and Goldman, A.S.:
Cystic Fibrosis of the Pancreas in Black Infants with Absence of
the Vas Deferens. The Black Bag,
Vol. 4, No. 1, March, 1975.
- Lanier, B.Q.,
Goldman, A.S., and Harris, N.A.:
Plasma Cell Antigen on the Surface of Lymphocytes in
Immunodeficient Patients (Abstract).
Presented to the Annual Meeting of the Reticuloendothelial Society,
1974.
- Lanier, B.Q.,
Daeschner, C.W.: Serious
Complications of Suprapubic Aspiration of the Urinary Bladder. J. Pediat.,
79: 711, 1971.
- Lanier, B.Q.,
Nghiem, Q.X., and Derick, J.R.:
Prolonged Partial Bypass for Correction of Recurrent Coarction of
the Aorta in a Patient with Unilateral Renal Agenesis.
---------------------------------------------- non cited
-------------------------------------
- Lanier,
B.Q.: "Apathy", Medical
Portfolio, Fall 1989.
- Lanier,
B.Q.: A Matter of Opinion "A
National Disgrace",
- Lanier, B.Q.:
"Doctors and Unions", Medical Portfolio Volume 8, No. 2, July
1988.
- Lanier, B.Q.:
"Homeless" Cortlandt Group, 1988.
- Lanier, B.Q.:
"Malpractice and Lawyers", Medical Portfolio, Volume 7, No. 1
1988
- Lanier, B.Q.:
"Malpractice Prevention", Medical Portfolio Volume 6, No. 3 1987.
- Lanier,
B.Q.: "Lawyer Bashing",
Medical Portfolio, Vol. 7, No. 3, Sept.1987.
- Lanier,
B.Q.: "The New
Charlatans", RTNDA Communicator, Fall 1987.
- Lanier, B.Q.: A
Matter of Opinion "Affluenza" and the Millitant Patient Syndrome,
Tarrant County Physician, March
1986.
- Lanier,
B.Q.: A Matter of Opinion
"Where Did We Go Wrong?"
- Lanier,
B.Q.: "Get to Know Your
Patients Before You Meet Them".
Medical Economics, Pg. 121-122, Nov. 1985.
- Lanier, B.Q.:
"Media Polls and HMO's", Medical Portfolio, Vol. 6, No. 1, Sept.
1985.
- Lanier, B.Q.:
"Hospitals and Ambulatory Medicine". Editorial, Medical
Portfolio, Vol. 5, No.3, Sept. 1984.
- Lanier, B.Q.:
"Patients Have a Ball With My Computer - And Learn a
- Lanier,
B.Q.: A Second Opinion
(commentary). Medical Portfolio, Vol. 4, No.2, October, 1983
- Lanier, B.Q.:
"Pitfalls of the Diagnosis Related Group Concept". Editorial,
Medical Portfolio, Vol. 3, No. 2, October, 1983
- Lanier,
Bobby: Sex Education - Minority
Report -
- Lanier,
Bobby: Editorial. Physicians and the Pharmaceutical
Industry, JAMA,
- Lanier, Bobby: Of Physicians and Technology (Editorial). Medical Portfolio for Allergists, Vol. 2, No. 2, September 1981.
RESEARCH PROJECTS
·
AstraZeneca D5360C00703
– Study to Assess the Safety and Efficacy of Rhinocort Aqua in patients
2-5 with AR
· Criterium MGP707- A Multi-center, Three Arm, Parallel group, Double-blind Placebo-controlled, randomized study of Bioequivalence and Efficacy of Fluticasone Propionate Nasal Spray Compared to Flonase Nasal Spray In Patients with Seasonal Allergic Rhinitis
·
Schering PO4095 – Efficacy and Safety of Combination
Loraradine/Monelukast QD vs Pseudoephedrine and Placebo in the Treatment of
Subjects with Seasonal Allergic rhinitis
· Alcon C-03-49 – Olopatadine VRS Astelin in patients with allergic rhinitis
· Symbio CPL-404 – Triamcinolone Acetonide Nasal Spray compared with Nasacort AQ
·
Alcon C-04-20 – Peds Study, Olopatadine Hydrochloride Nasal
Spray versus Placebo
·
Altana Pharma BY90101/M1-403
- Study to Assess the Safety and Efficacy of Ciclesonide Nasal Spray vs.
Placebo in Children 6 - 11 with PAR.
· ALTANA Pharma BY217/M2-023 – Roflumilast versus Placebo
· AstraZeneca D5896C0005 – Symbicort versus Advair
· Alcon C-01-92 – Long Term Safety Study of Olopatadine Nasal Spray
· AstraZeneca SD-004-0764 – Comparing the Efficacy and Safety of Pulmicort Respules at different dosages and the Pulmicort Turbuhaler in patients ages 12 years and older with moderate to severe asthma.
·
AstraZeneca SD-004-0726
– Comparison of Pulmicort Turbuhaler and the New Version of Pulmicort
Turbuhaler in Asthmatic Children and Adolescents.
· ALTANA Pharma BY9010/M1-402 – Study to Assess the Safety and Efficacy of Ciclesonide Nasal Spray vs. Placebo in Patients 12 and Older with PAR.
· Dey D1-055 – Pediatric Study comparing Formoterol Fumarate Inhalation Solution and Formoterol Dry Powder Inhaler; placebo controlled.
· Sepracor 051-354 – An Efficacy, Safety, and Tolerability Study of daily dosing with Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects (4-11 years) with Asthma.
· Aventis MO16455P/3001- Study to assess the efficacy and safety of Fexofenadine with subjects with mild to moderate persistent asthma.
· Aventis MO16455P/3003 – Study to assess the long-term safety performance of Fexofenadine compared to Montelukast.
· Aventis XRG5029C/4007 – Comparing the Efficacy of Nasacort AZ with Rhinocort for the Treatment of Seasonal Allergic Rhinitis Symptoms in patients 12-65 years of age.
· Novartis CFOR258D2307 – Evaluating safety and efficacy of treatment with 24 mcg bid and 12 mcg bid formoterol, and 12 mcg bid formoterol with additional on-demand doses in adolescent and adult patients with persistent stable asthma.
· Astra Zeneca SD-039-0718 – Symbicort versus its Mono-Products (budesonide and formoterol) in Asthmatic Children Aged 6 – 15 yrs.
· Astra Zeneca SD-004-0620 – Comparison of Pulmicort Turbuhaler and the New Version of Pulmicort Turbuhaler in Asthmatic Adults
· Sepracor 051-353 – Efficacy and Safety Study of Levalbuterol, Racemic Albuterol in subjects 12 years and older.
· Aventis XRP1526B-341 – Ciclesonide Metered Dose Inhaler in the treatment of children with persistent asthma.
· GlaxoSmithKline SAS40036 – Comparison of Asthma Control in adolescents and adults receiving either Fluticasone Propionate/Salmeterol Diskus combination product, Fluticasone Propionate Diskus, Salmeterol Xinafoate Diskus, or Oral Montelukast.
· Aventis HMR3647A/3014 – Oral Telithromycin and Amoxicillin/Clavulanic Acid in outpatients with respiratory tract infections in usual care settings.
· Novartis FOR258F0604 – Evaluating the safety, efficacy, and pharmacokinetics of Foradil versus placebo.
· Sepracor 110-073 – A Double-Blind, Placebo and Active-Controlled, Parallel Group Study of Tecastemezole.
· Schering-Plough PO1861 – A Placebo and Active Controlled Efficacy and Safety Study of Desloratadine/Pseudoephedrine.
·
Genentech, Inc. Q2461g – An open-label study II of of Omalizumab in moderate to severe,
persistent asthma subjects.
·
Genentech, Inc. Q2195g
– An open-label extension study of Omalizumab in moderate to
severe, persistent asthma subjects.
·
Genentech, Inc. Q2143g – An open label study to evaluate
the safety of Omalizumab in moderate to severe, persistent
asthma subjects.
·
Schering S83-022 - A Comparison of Two Major
Treatment Modalities in the Therapy of Exercise Induced Asthma
·
Schering S85-035 - A Study of the Safety and
Efficacy of Loratadine Plus Pseudoephedrine Compared with Placebo in Patients
with Seasonal Allergic Rhinitis
·
Schering S87-001 SCH 434 - Loratadine Plus Pseudoephedrine) Versus
Tavist-D in Seasonal Allergic Rhinitis
·
Warner-Lambert/Parke-Davis 184-56 - A Two-Week, Multicenter, Double-Blind,
Dose-Ranging Study of the Comparative
Efficacy and Safety of Low Dose Sustained Release Benadryl, Standard-Release
Benadryl, and Placebo in Outpatients with Allergic Rhinitis
·
Schering S88-001 - Once Daily Claritin vs. Benadryl, Three Times Daily, Verses Placebo
·
Schering S88-047-03 - Loratadine Tablets vs Loratadine Capsules vs Placebo in Seasonal
Allergic Rhinitis
·
Schering-Plough C91-105-103 - A Patient Preference Study of
Vanceril MDI vs Azmacort MDI
·
Parke-Davis 888-201 - A Multicenter Double-Blind Three Month Study of the Comparative
Efficacy and Safety of Procaterol and Albuterol Aerosol Administered QID in Outpatients with Reversible
Bronchial Airway Obstruction
·
Rhone-Poulenc Rorer 5016-117 - A Cohort Epidemiologic Study to Determine the
Effect of One Year of Azmacort
(Triamcinolone Acetonide) or Alternate Day Prednisone or Alternate Day
Prednisone Plus Azmacort or Nonsteroidal Antiasthmatic Therapy on Growth Patterns
of Asthmatic Children
· Glaxo FLI-302 - A Randomized Double-Blind Comparative Trial of Inhaled Fluticasone Propionate Versus Theophylline Verses Placebo in Adolescent and Adult Patients with Mild to Moderate Asthma
· Carter Wallace 368 – A Randomized, Double-Blind Study of Astelin Nasal Spray versus Combination Therapy Nasal Steroid and Oral Antihistamines in Subjects with Seasonal Allergic Rhinitis.
· Aventis MO16455C/3212 - A Double-blind, Randomized, Placebo-controlled, Parallel Group Study Assessing the Efficacy and Safety of Fexofenadine in Pediatric Subjects.
· Aventis MO16455I/3112 – A Multicenter, Double-Blind, Randomized, Placebo-controlled. Parallel Study to Assess the Safety and Tolerability of Fexofenadinein Children ages 2 through 5.
· Aventis MO16455I/3112B– A Multicenter, Double-Blind, Randomized, Placebo-controlled. Parallel Study to Assess the Safety and Tolerability of Fexofenadinein Children ages 2 through 5.
· Aventis MO16455P/2113 – A Multi-center, Doulbe-Blind, Randomized, Parallel Groups Placebo-controlled Pilot Study to Observe the Effects of Montelukast in combination with Fexofenadine on Persistent Mild to Moderate Asthma Subjects.
·
Glaxo Wellcome FDP40012- A
Randomized, Double-Blind, Double Dummy, Parallel Group Comparison of
Fluticasone Inhalation Powder via Diskus with Oral Montelukast Chewable Tablets
in Children ages 6-12 with Persistent Asthma.
· GlaxoSmithKline SAM40027 – A Multicenter, Stratified, Randomized, Double-Blind, Parallel Group, Step-up Comparison of the Level of Asthma Control Achieved with Salmeterol/Fluticasone Combination Diskus compared with Fluticasone Diskus Alone in Adults and Adolescents.
·
Glaxo Wellcome SAS40026 –
A Randomized, Double-Blind, Parallel Group, Comparative Trial of
Salmeterol/Fluticasone Combination Diskus Versus Fluticasone inhaler in Adolescents
and Adults with Moderate Persistent Asthma
·
Glaxo Wellcome SAS40021 –
A Randomized, Double-Blind, Double-Dummy, Parallel Group, 12 Week
Comparative Trial of Salmeteral/Fluticasone Combination Diskus Versus Oral
Montelukast in Adolescents and Adults with Persistent Asthma.
·
Glaxo Wellcome FMS30058 –
A Multicenter, Randomized, Doulbe-Blind, Parallel group,
Placebo-controlled, 12 –week Study of Fluticasone Propionate Delivered
CFC MDI and a Valved Holding Chamber with Facemask in Subjects Age 24 Months to
47 Months with Asthma.
·
Glaxo Wellcome FMS30059 - A
Multicenter, Randomized, Doulbe-Blind, Parallel group, Placebo-controlled, 12
–week Study of Fluticasone Propionate Delivered CFC MDI and a Valved
Holding Chamber with Facemask in Subjects Age 6 Months to 23 Months with
Asthma.
·
Immunex 13.0019 – Phase
II Efficacy Study of Nebulized Recombination Human IL-4 Receptor in Asthma
Patients using Inhaled Corticosteriods.
·
Millennium M97700-023 –
A Phase II, Randomized, Placebo-controlled, Double-Blind, Parallel group
Dose-Finding Study to Evaluate the Effectiveness of Treatment with LDP-977 in
Adult Asthmatics.
· Amyllin 137-122 - A Double-Blind, Placebo-controlled, Multicenter, Phase III Study to Evaluate the Effects of Pramlintide in Patients with Type II Diabetes Mellitus.
· Alcon C-99-37 – A Randomized, Controlled Study to Evaluate the Safety and Efficacy of Topical Cipro Compared to Cortisporin for treatment of Acute Otis Externa.
· Alcon C-00-33 – A Placebo-controlled, Environmental Study of Patanol Nasal Spray versus Astelin Nasal Spray in Subjects with Seasonal Allergic Rhinitis.
·
·
3M 1343-BRON – A
12-week Comparison of Daily Dose of Beclomethesone Dipropionate versus Placebo
in Autohaler Device in Pediatric Patients with Symptomatic Asthma.
·
3M 1332-SILV – Safety
and Efficacy Study of Albuterol Sulfate Delivered from a Press and Breath MDI,
the Autohaler and Placebo in Patients with Asthma.
·
Sepracor 091-004 – A
Safety, Efficacy and Tolerability Study of Multiple Once-Daily Doses of Fometerol Inhalation Solution in Subjects
with Asthma.
·
Schering Plough PO1998-21- Efficacy
and Safety of Combination Loratadine/Monelukast versus Its Components in the
Treatment of Subjects Seasonal Allergic Rhinitis.
·
Schering Plough PO1545-16
– Placebo-controlled Efficacy and Safety Study of a Once- Daily and
Twice-Daily Regimens of Mometasone Furoate via Dry Powder Inhaler in Subjects
with Asthma Previously Maintained on Inhaled Corticosteroids.
·
Schering Plough PO00687-09
– Efficacy and Safety of SCH29851 in Subjects with Seasonal Allergic
Rhinitis.
·
Schering Plough PO0216-27
– Efficacy and Safety of SCH34117 in Patients with Seasonal Allergic
Rhinitis and Concurrent Asthma.
·
Rhone-Poulenc Rorer RG5016Y-204
– A Phase II/III Double-Blind, Placebo-Controlled, Parallel Group,
Multicenter Efficacy, Safety and Dose Response Study of Azmacort Inhalation
Aerosol in treatment of Mild and Moderate Persistent Asthma in Adolescents and
Adults.
· Pfizer A3771001 – A Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study of the Efficacy and Safety of Cetrizine-Pseudoephedrine versus Loratadine-Pseutophedrine versus Placebo in the Treatment of Subjects 12 and Older with Seasonal Allergic Rhinitis.
·
G.H. Besselaar Associates GHBA-168 -
(Astra Draco 04-3022) A Double-Blind,
Randomized, Placebo-Controlled Study to Determine the Efficacy and Safety of
Three Different Doses of Pulmicort (Budesonide) Turbuhaler in Pediatric
Patients with Glucocorticosteroid
Treated Asthma
·
Glaxo SLGA 5003 - A Randomized, Double-Blind, Parallel Group
Evaluation of the
Safety, Efficacy, and Effect
on Asthma Quality of Life of Salmeterol Versus
Albuterol in Inhaled Corticosteroid-Free and Inhaled Corticosteroid-Treated
Asthma Subjects
·
Astra
Nebulizing Suspension and
Placebo in Asthmatic Children Aged Between Four
and Eight Years
·
Merck MK-0476 - A Multicenter, Double-Blind, Randomized, Parallel-Group Study
Comparing the Clinical Effect of Three Oral Doses of MK-0476 and Placebo in
Adult
Patients with Stable,
Moderate Asthma
·
Rhone-Poulenc Rorer RG-5016T-203 - A Double-Blind, Dose-Ranging Study of
Azmacort HFA-134a Oral
Inhaler Compared to Azmacort Oral Inhaler in the
Treatment of Asthma in Children
·
Glaxo SLGA5017 - A Comparison of Adding Serevent Versus
Doubling the
Dose of Beclovent in
Asthmatic Subjects Symptomatic on Their Existing
Inhaled Corticosteroids
·
Glaxo FLTA2008 - A
Randomized, Double-Blind, Parallel-Group Trial Assessing the
Efficacy and Safety of
Fluticasone Propionate via the Multi-Dose Powder
Inhaler 100MCG BID, 200 MCG
QD, and Placebo in Subjects Aged 4 to 11
Years with Chronic Asthma
·
SmithKline Beecham Pharmaceuticals
SB 205312/012 -A Multi-Center,
Double-Blind,
Placebo-Controlled, Parallel Group Comparison of the Safety
and Efficacy of Oral Twice
Daily Administration of SB 205312 with Inhaled
Tilade in Patients with Mild to Moderate
Asthma
·
Rhone-Poulenc Rorer RG5029Y A
Randomized, Placebo-controlled, Parallel Group,
Multiple-Dose Study of
RG5029Y on Hypothalamic-Pituitary-Adrenal (HPA)
Function and Pharmacokinetic
Profile in Pediatric Patients with Allergic Rhinitis
·
SmithKline Beecham Pharmaceuticals
SB 205312-084 A Multi-Center,
Double-Blind, Placebo-Controlled, Parallel Group Study of Evaluate the
Safety
and Efficacy of Oral Twice
Daily Administration of SB 205312 in Pediatric Patients
with Mild to Moderate Asthma
· Glaxo FLTA2006 A Randomized, Double-Blind, Double Dummy,
Parallel-Group Trial Assessing the Efficacy and Safety of Fluticasone Propionate 50 or 100 mcg BID Via the Multi-Dose Powder Inhaler, Fluticasone Propionate 50 or 100 mcg BID Via the Diskhaler and Placebo in Subjects Aged 4 to 11 Years with
Chronic Asthma
·
SmithKline Beecham Pharmaceuticals SB
205312-087 A Multi-Center, Open
Label, Long Term Study of the Safety, Tolerability and Efficacy of Oral SB
205312 in Pediatric Patients with Mild to Moderate Asthma
·
Glaxo Wellcome FLTA4015 A
Randomized, Double-Blind, Parallel-Group, Comparative Trial of inhaled
Fluticasone Propionate (84 mcg and 336 mcg BID) Via the Metered-Dose Inhaler in
Asthmatic Subjects Previously Treated with Beclomethasone Dipropionate
·
Hoechst Marion Roussel PJPR0053 A
Double-Blind, Randomized Study Comparing the Efficacy and Safety of
Fexafenadine and Placebo in Black Patients with Seasonal Allergic Rhinitis
·
TAP Pharmaceuticals M94-216 Safety
and Efficacy of AA-2414 (ABT-001) in Patients with Moderate Asthma
·
SmithKline Beecham Pharmaceuticals
SB 205312-080 A double-blind, double dummy,
placebo-controlled, randomized, parallel group study to examine the effects of
oral SB 205312 mg BID in patients with asthma and concomitant seasonal allergic
rhinitis - a comparison to patients taking inhaled Vanceril 168 mcg BID and as
required nasal rescue medication
·
Sepracor 051-024 A Phase
III Randomized, Double-blind, Placebo-Controlled, Parallel-Group Study of the
effects of (R)-Albuterol in the Reversal of Bronchoconstriction and in the
Management of Asthma
·
SmithKline Beecham Pharmaceuticals
SB 205312-07 A Multicenter,
Double-blind, Placebo-Controlled, Parallel Group Study To Evaluate The Safety
And Efficacy Of Two Doses Of SB 205312 Administered As An Oral Suspension (75
MG BID And 150 MB BID) for 12 Weeks In Pediatric Out-Patients With Asthma
·
Glaxo Wellcome SLGA 5021 A Randomized, Double-blind
Clinical Trial Comparing The Efficacy And Safety Of Salmeterol Xinafoate 42 MCG
BID Plus Fluticasone Propionate 88 MCG BID Alone In Subjects with Asthma Not
Well controlled On Fluticasone Propionate 88 MCG BID
·
Ciba-Geigy Corporation 51901 01 04 A Double-blind, Randomized,
Parallel-Group, placebo-Controlled, Multiple-Dose (Intravenous Infusions of 35
MG, 58 MG, or 93 MG CGP 51901 Q 2 Weeks x 6) Multicenter Pilot Trial To Assess
The Efficacy, Safety, Tolerability, Pharmacokinetics, And Biologic Activity of
CGP 51901 In Patients 18-40 Years Old With Mild To Moderate Perennial Allergic
Asthma
·
GlaxoWellcome FLTA 4025 A
Randomized, Double-Blind, Placebo-controlled Study Examining The Effect Of
Fluticasone Propionate Aqueous Nasal Spray 200 MCG QD Used In Conjunction With
An Antibiotic In Allergic Subjects With Recurrent Sinusitis
·
Novartis 049 A
Twelve-month, Double-Blind, Between-Patient, Placebo-Controlled Trial Comparing
the Safety, Tolerability and Efficacy of 12 ug and 24 ug and 24 ug Twice Daily
Formoterol Dry Powder Capsules for Inhalation Delivered by a Single-Dose
Inhaler (Aerolizer) in Children With Asthma in Need of Daily Treatment with
Inhaled Bronchodilators and Anti-Inflammatory Treatment
·
Glaxo SFCA 3003 A
Randomized, Double-Blind Trial Evaluating safety and Efficacy of Salmeterol 50
mcg BID and Fluticasone Propionate 250mcg BID Individually and in Combination
and Placebo in Patients with Asthma
·
Abbott M96-464 Long
Term Safety Study of Zileuton Controlled-Release Plus Usual Care Versus Placebo
Plus Usual Care in Patients with Asthma
·
Novartis Pharmaceuticals rhuMAb-E25
01 006 - A Phase IIb,
Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose (Subcutaneous
Administrations of 50 mg, 150, mg or 300 mg), Multicenter, Dose-Ranging Trial
To Assess The Efficacy, Safety, Tolerability, Pharmacokinetics And Biological
Effect Of Anti-Ige Recombinant Humanized Monoclonal Antibody-E25 (rhuMAb-E25)
Versus Placebo For Symptoms Effect Of Anti IgE Recombinant Humanized Monclonal
Antibody-E-25 (rhuMAb-E25) Versus Placebo For Symptom Prevention In Patients
With Ragweed Induced Seasonal Allergic Rhinitis”
·
Astra Merck 153 - Comparison of the Safety and Antihypertensive
Efficacy of the Fixed Combination of Candesartan Cilexetil and
Hydrochlorothiazide (32/12.5 mg) Once Daily with the Individual Components
Administered Once Daily: A Multicenter, Randomized, Double-Blind, Placebo
Controlled, Parallel-Design Study
·
Pfizer L-0350, An open Label, Multicenter Study of the
Efficacy, Safety, and effect on Quality of Life of Zyrtec® (certirizine HCL)
Syrup in the Treatment of Seasonal Allergic Rhinitis in Children
·
Hoechst Marion Roussel MO16455B /
3081 - A Double-blind
Randomized, Placebo-Controlled Parallel Study comparing the Efficacy and Safety
of Fexofenadine HC1 120 mg And 180 mg QD In The Treatment Of Autumn Seasonal
Allergic Rhinitis
·
Schering-PloughC97- 223-16 - Placebo-Controlled Efficacy and Safety Study
with Long-Term Safety Evaluation of Mometasone Furoate HFA-227 Metered Dose
Inhaler in the Treatment of Asthma in Subjects Previously Maintained on Inhaled
Beta-Agonists
·
· GlaxoWellcome FLTA 4030 - A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group, Comparative Study of Inhaled Fluticasone Propionate (88 mcg BID) Versus Zafirlukast (20mcg BID), in Subjects Who are Currently Receiving Beta Agonista Alone
·
Astra Merck 175 - Evaluation of the Antihypertensive Effect of
Candesartan Cilexetil
in Comparison to Losartan
·
ViroPharma 843-013 - A Double-Blind, Placebo Controlled Exploratory
Evaluation
of Pleconaril (VP-63843) in the Treatment of
Rhinovirus Upper Respiratory Tract
Infections in Patients with
Moderately Severe Bronchial Asthma
·
GlaxoWellcome FLTA 4035 - A
Randomized, Double-Blind, Double-Dummy, Parallel Group, Comparative Study of
Inhaled Fluticasone Propionate 88 Mcg BID Versus Zafirlukast 20 Mg BID in
Asthmatic Subjects Who Are Currently Receiving Low Dose Inhaled Corticosteroids
·
Novartis Pharmaceuticals rhuMAb-E25
01 008 - A Phase III, 7 Month,
Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Trial
With a 5-Month Blinded Extension Period To Assess the Efficacy, Safety,
Tolerability, Steroid-Reduction, Pharmacokinetics, and Pharmacodynamics of
Subcutaneous rhuMAb-E25 in Adolescents and Adults With Moderate To Severe
Allergic Asthma Requiring Daily Treatment With Inhaled Corticosteroids
·
Wallace 368 - A
Randomized, Double-Blind Study of Astelin® Nasal Spray Monotherapy Versus Combination
Therapy of A Nasal Steroid and Oral Antihistamine in Subjects With Seasonal
Allergic Rhinitis
·
Astra Merck Inc. 183 - A Multicenter, Double-Blind, Randomized,
Placebo-Controlled Study to Investigate the Safety and Efficacy of Omeprazole,
10 mg QD,
in Preventing Heartburn
·
Novartis Pharmaceuticals rhuMAb-E25
01 010 - A Phase III, 7 Month,
Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multicenter Trial
With a 5-Month Open-Label Extension Period To Assess Safety and Tolerability, Steroid-Reduction,
Pharmac cokinetics, and Pharmacodynamics of Subcutaneous rhuMAb-E25 in Children
(6-12 years) With Allergic Asthma Requiring Daily Treatment With Inhaled
Corticosteroids
·
Novartis Pharmaceuticals rhuMAb-E25
01 010 Extension- A Phase III, 7
Month, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled,
Multicenter Trial With a 5-Month Open-Label Extension Period To Assess Safety and Tolerability, Steroid-Reduction,
Pharmac cokinetics, and Pharmacodynamics of Subcutaneous rhuMAb-E25 in Children
(6-12 years) With Allergic Asthma Requiring Daily Treatment With Inhaled
Corticosteroids
·
Alcon C98-19 - Topical CILODEX™ (ciprofloxacin 0.3%,
dexamethasone 0.1%) Suspension Compared to CORTISPORIN® Suspension (neomycin
0.35%, ploymyxin, 10,000 IU mL, Hydrocortisone 1.0%) for Treatment of Patients
with Acute Otitis Externa (AOE)
·
Alcon C98-04 - An Observer-Masked Adjunctive Therapy
Environmental Study of Patanol With Claritin Versus Claritin Alone in Patients
With Seasonal Allergic Conjunctivitis
·
Rhone-Poulenc Rorer 5016Y-204 - A Phase II/III Double Blind
Placebo-Controlled, Parallel-Group, Multicenter Efficacy, Safety and Dose
Response Study of Azmacort (triamcinolone acetonide) HFA-134a Inhalation
Aerosol 225 mcg, 450 mcg and
900 mcg Administered Once Daily for 12 weeks in the Treatment of Mild
Persistent
and Moderate Persistent
Asthma in 800 Adolescents and Adults
·
Novartis 009 - A Phase III, 7-Month, Randomized,
Double-Blind, Parallel-Group, Placebo-Controlled, Multi-Center Trial with a
5-Month Blinded Extension Period to Assess The Efficacy, Safety, Tolerability,
Steroid-Reduction, Pharmacokinetics of Subcutaneous rhu-MAB-E25 in Adolescents
and Adults With Moderate to Severe Allergic Asthma Requiring Daily Treatment
With Inhaled Corticosteroids.
·
Pfizer 362 - A Randomized, Double-Blind, Placebo
Controlled, Multi-Center Study of the Efficacy, Safety, and Effect on Quality
of Live, Work Productivity and Activity Impairment of Zyrtec vs. (Cetirizine
HCI) vs. Placebo in the Treatment of
Seasonal Allergic Rhinitis
·
FLTA 4038 - A Randomized, Double-Blind, Parallel Group
Comparison Study of Inhaled Fluticasone Propionate (88mcg BID) Versus
Montelukast Sodium (10mg QD) in Subjects Currently Receiving Beta Agonists
Alone
·
GlaxoWellcome 40004 - A Randomized, Double-Blind, Double-Dummy,
Parallel Group Comparison of Salmeterol Xinafoate Inhalation Powder (50mcg BID)
With Oral Montelukast (10mg QD) In Subjects With Persistent Asthma Symptomatic
on Concomitant Inhaled Corticosteroid Therapy
·
GlaxoWellcome 30004 - A Randomized, Double-Blind,
Placebo-Controlled, Parallel-Group 12-Week Trial Evaluating the Safety and
Efficacy of Salmeterol/Fluticasone Propionate Combination in GR106642X MDI,
50/250mcg BID, and Salmeterol in Propellant 11/12MDI, 50mcg BID, and
Fluticasone Propionate in Propellant 11/12MDI, 250mcg BID, and Placebo in
Propellant GR106642X in Adolescent and Adult Subjects with Asthma
ONGOING RESEARCH PROJECTS
·
Novartis CIGE025AUS23- A 26-week, Randomized, Double-blind,
Parallel-group, Placebo-controlled, Multi-center, Study to Evaluate the Effect
of Xolair (Omalizumab) on Improving the Tolerability of Specific Immunotherapy
in Patients with Persistent Allergic Asthma
· Alcon C-05-69: 12 month safety study of Olopatadine Nasal Spray
·
Schering Plough P04824-efficacy/safety of MFNS vs placebo as
adjunctive treatment to antibiotics in relief of symptoms of acute bacterial
sinusitis
·
Sanofi Aventis EFC6695-efficacy/safety of ciclesonide metered-dose
inhaler at 80 mcg BID vs 40 mcg BID vs placebo in children 4 to 11 yrs
·
Sanofi Aventis XRG5029C/3503-12 month effect of treatment
with QD triamcinolone acetonide on growth velocity of children 3-8 yrs with SAR
·
Amgen Inc. AMG317-safety/efficacy of AMG317 in subjects with
moderate to severe asthma
·
Genentech Q3663g – A
·
· Novartis IGE025A US23-Omalizumab efficacy on improving tolerability of specific immunotherapy in patients with persistent allergic asthma
·
Genentech Q2948g – An Epidemiologic study of Xolair
Evaluating Effectiveness and Long-Term Safety in Patients with Moderate to
Severe Asthma
·
Novatris CIGE025AIA05 – An Evaluation of Efficacy, Safety,
Pharmacokinetics and Pharmacodynamics of Omalzumab in Children 6-12 with
Moderate-Severe Persistent Asthma